Perifosine: Final Phase I data

Final data from a Phase I trial in 30 evaluable patients showed that perifosine plus Revlimid lenalidomide and dexamethasone produced an objective response rate (ORR) of 73%, including 4 near complete responses, 3 very good partial responses, 8 partial responses and 7 minimal responses, plus 6 cases of stable disease. Median progression-free survival (PFS) and overall survival (OS) were 10.8 and 30.6 months, respectively. Data were presented at the American Society of Hematology meeting in Orlando. ...